Phase I/II Randomized, Double Blind, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Subcutaneous Bay 50-4798 Administration in Patients With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to Patients on HAART Alone
Latest Information Update: 03 Nov 2021
At a glance
- Drugs AIC 284 (Primary) ; Antiretrovirals
- Indications HIV infections
- Focus Adverse reactions
- 26 May 2009 ClinicalTrials.gov has reported actual end date (Mar 2005) added and actual patient number (82) added.
- 26 May 2009 ClinicalTrials.gov has reported actual end date (Mar 2005) added and actual patient number (82) added.
- 26 May 2009 Additional location identified as reported by ClinicalTrials.gov.